Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Treatments in Myocardial Ischemia, Valvular Heart Diseases, and Heart Failure
share announcement

Treatments in Myocardial Ischemia, Valvular Heart Diseases, and Heart Failure

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (15 January 2022) | Viewed by 7950

Special Issue Editors

Prof. Dr. Daniel Hernandez-Vaquero

E-Mail
Guest Editor
Hospital Universitario Central de Asturias, University of Oviedo, 33011 Oviedo, Spain
Interests: cardiac surgery; structural heart disease
Prof. Dr. Pablo Avanzas

E-Mail Website
Guest Editor
Hospital Universitario Central de Asturias, University of Oviedo, 33011 Oviedo, Spain
Interests: cardiology; interventional cardiology; structural heart disease

Special Issue Information

Dear Colleagues,

Cardiovascular diseases are responsible for almost 18 million deaths annually, which represents around 30% of total yearly mortality. Heart disease is the number one cause of death in the USA, and within this group, heart failure, valvular heart disease, and myocardial ischemia are some of the most important entities. In recent years, we have witnessed new, extraordinary, and promising medical and surgical treatments to treat and prevent these three entities. In this issue, we welcome systematic or literature reviews and original articles focused on the treatment of heart failure, valvular heart diseases, and myocardial ischemia. Articles or meta-analyses on new medical devices or treatments are especially welcome, but all of them must be methodologically sound and rigorous.

Prof. Dr. Daniel Hernandez-Vaquero
Prof. Dr. Pablo Avanzas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • myocardial ischemia
  • valvular heart disease

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 10401 KiB  
Article
Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance
by Marc Llagostera-Martín, Hector Cubero-Gallego, Aleksandra Mas-Stachurska, Neus Salvatella, Andrea Sánchez-Carpintero, Helena Tizon-Marcos, Marcos Garcia-Guimaraes, Alicia Calvo-Fernandez, Luis Molina and Beatriz Vaquerizo
J. Clin. Med. 2021, 10(7), 1421; https://doi.org/10.3390/jcm10071421 - 01 Apr 2021
Cited by 1 | Viewed by 1947
Abstract
The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This [...] Read more.
The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbreTM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9.4 years), with a high proportion of comorbidities. The mean CHA2DS2-VASc and HAS-BLED scores were 4.6 ± 1.6 and 3.9 ± 1.0, respectively. Previous history of a major bleeding event was present in 37 patients (67.3%). Procedural success was achieved in 54 patients (98.2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1.8%) and pericardial tamponade in two patients (3.6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1.8%), transient ischemic attack/ischemic stroke (1.8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbreTM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance. Full article
(This article belongs to the Special Issue Treatments in Myocardial Ischemia, Valvular Heart Diseases, and Heart Failure)
►▼ Show Figures

Figure 1

12 pages, 1499 KiB  
Article
Premature STEMI in Men and Women: Current Clinical Features and Improvements in Management and Prognosis
by Rebeca Lorca, Isaac Pascual, Andrea Aparicio, Alejandro Junco-Vicente, Rut Alvarez-Velasco, Noemi Barja, Luis Roces, Alfonso Suárez-Cuervo, Rocio Diaz, Cesar Moris, Daniel Hernandez-Vaquero and Pablo Avanzas
J. Clin. Med. 2021, 10(6), 1314; https://doi.org/10.3390/jcm10061314 - 23 Mar 2021
Cited by 5 | Viewed by 2110
Abstract
Background: Coronary artery disease (CAD) is the most frequent cause of ST-segment elevation myocardial infarction (STEMI). Etiopathogenic and prognostic characteristics in young patients may differ from older patients and young women may present worse outcomes than men. We aimed to evaluate the clinical [...] Read more.
Background: Coronary artery disease (CAD) is the most frequent cause of ST-segment elevation myocardial infarction (STEMI). Etiopathogenic and prognostic characteristics in young patients may differ from older patients and young women may present worse outcomes than men. We aimed to evaluate the clinical characteristics and prognosis of men and women with premature STEMI. Methods: A total 1404 consecutive patients were referred to our institution for emergency cardiac catheterization due to STEMI suspicion (1 January 2014–31 December 2018). Patients with confirmed premature (<55 years old in men and <60 in women) STEMI (366 patients, 83% men and 17% women) were included (359 atherothrombotic and 7 spontaneous coronary artery dissection (SCAD)). Results: Premature STEMI patients had a high prevalence of classical cardiovascular risk factors. Mean follow-up was 4.1 years (±1.75 SD). Mortality rates, re-hospitalization, and hospital stay showed no significant differences between sexes. More than 10% of women with premature STEMI suffered SCAD. There were no significant differences between sexes, neither among cholesterol levels nor in hypolipemiant therapy. The global survival rates were similar to that expected in the general population of the same sex and age in our region with a significantly higher excess of mortality at 6 years among men compared with the general population. Conclusion: Our results showed a high incidence of cardiovascular risk factors, a high prevalence of SCAD among young women, and a generally good prognosis after standardized treatment. During follow-up, 23% suffered a major cardiovascular event (MACE), without significant differences between sexes and observed survival at 1, 3, and 6 years of follow-up was 96.57% (95% CI 94.04–98.04), 95.64% (95% CI 92.87–97.35), and 94.5% (95% CI 91.12–97.66). An extra effort to prevent/delay STEMI should be invested focusing on smoking avoidance and optimal hypolipemiant treatment both in primary and secondary prevention. Full article
(This article belongs to the Special Issue Treatments in Myocardial Ischemia, Valvular Heart Diseases, and Heart Failure)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 5050 KiB  
Review
Mitral Paravalvular Leak: Clinical Implications, Diagnosis and Management
by Ignacio Cruz-Gonzalez, Pablo Antunez-Muiños, Sergio Lopez-Tejero and Pedro L. Sanchez
J. Clin. Med. 2022, 11(5), 1245; https://doi.org/10.3390/jcm11051245 - 25 Feb 2022
Cited by 5 | Viewed by 3035
Abstract
Paravalvular leak incidence after mitral surgical replacement ranges from 7% to 17%. Between 1% and 5% of these are clinically significant. Large PVLs can cause important clinical manifestations such as heart failure or haemolysis. Current guidelines consider that surgical reparation is the gold-standard [...] Read more.
Paravalvular leak incidence after mitral surgical replacement ranges from 7% to 17%. Between 1% and 5% of these are clinically significant. Large PVLs can cause important clinical manifestations such as heart failure or haemolysis. Current guidelines consider that surgical reparation is the gold-standard therapy in symptomatic patients with paravalvular leak. However, these recommendations are based in non-randomized observational registries. On the other hand, transcatheter paravalvular leak closure has shown excellent results with a low rate of complications, and nowadays it is considered the first option in selected patients in some experienced centres. In this review, we summarize the clinical manifestations, diagnosis, procedural details, and results of transcatheter mitral PVL closure. Full article
(This article belongs to the Special Issue Treatments in Myocardial Ischemia, Valvular Heart Diseases, and Heart Failure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop